Related Experiment Video
Updated: Jul 3, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.2K
Adjuvant Stereotactic Radiosurgery for Clear Cell Meningiomas
Zhishuo Wei1, Shalini G Jose2, Prateek Agarwal2
1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
World Neurosurgery
|February 15, 2024
Summary
Stereotactic radiosurgery (SRS) offers effective tumor control for clear cell meningiomas (CCM) after surgery. Multiple SRS treatments may be needed for sustained control of aggressive CCM, with 5 of 6 patients achieving it.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Clear cell meningiomas (CCM) are uncommon and aggressive tumors.
- CCM exhibit high recurrence rates post-resection.
Purpose of the Study:
- To evaluate the adjuvant benefit of stereotactic radiosurgery (SRS) for residual or recurrent clear cell meningiomas (CCM).
Main Methods:
- Retrospective review of 6 patients with Grade 2 CCM treated with SRS.
- Median SRS dose of 13 Gy (range: 10-15 Gy) with median follow-up of 35.5 months.
Main Results:
- Tumor control achieved in 5 of 6 patients after one or more SRS procedures.
- Three patients required additional SRS for tumor progression.
- One patient experienced a suspected adverse radiation effect managed with medication.
Conclusions:
- SRS is a viable adjuvant treatment for CCM post-resection.
- Higher margin doses and early intervention with SRS may improve outcomes.
- Multiple SRS sessions might be necessary for sustained tumor control in CCM patients.
